Clinical trials: Pneumonia, Aspiration
COVID-19
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
This is a Phase 1 and phase 2, adaptive, placebo-controlled, double-blind, randomized single-dose study in participants with Severe COVID-19 illness.
- Trial name
- NCT05303376
- Testing
- IBIO123
- Where
- 5 sites in South Africa, Ukraine
- Volunteers
- 123 people
- Sponsor
- Immune Biosolutions Inc